Best Supplements to Take With NAD+

NAD+ Works Only as Fast as the System Around It

Most supplements work by sending a signal. NAD+ does something fundamentally different. It is consumed, completely and irreversibly, every time one of its target enzymes runs through a single catalytic cycle. Sirtuins, the proteins that regulate gene expression and stress resistance, use it up. PARP enzymes, which repair broken DNA strands, use it up. The mitochondrial machinery that converts food into energy uses it up. Every cycle of every one of these processes takes one molecule of NAD+ out of the available pool.

That is the defining pharmacological fact about NAD+, and it is what makes the supplement picture here different from anything in the GLP-1 or GH secretagogue families. A GLP-1 receptor agonist like semaglutide binds a receptor and holds it; it is dosed weekly because it lingers. NAD+ cannot do that. It operates as a concentration-dependent throttle: the more is available, the faster the enzymes run; the less is available, the slower everything goes. Quantity is the mechanism. This is why restoring the pool matters, and it is why supplementing without attending to what builds, recycles, and depletes that pool can leave a person paying for a cosubstrate their body consumes almost as fast as it arrives.

There are three levers the body uses to manage the NAD+ pool. It builds NAD+ from precursors through several biosynthetic routes, the most important of which requires a rate-limiting salvage enzyme that slows down with age. It recycles NAD+ metabolites back into the pool through the salvage pathway, which requires magnesium and several B vitamins to function. And it loses NAD+ to enzymes like CD38, which cleave NAD+ to produce calcium-signaling molecules, and whose activity climbs steadily with age and inflammation.

What this means practically: a person running NAD+ with low magnesium has a synthesis bottleneck at the assembly step. A person without adequate methylation support will see homocysteine climb as their increased NAD+ metabolism draws on methyl groups the rest of their nutrition is not replenishing. And a person who does nothing to slow CD38 is accelerating the degradation side of the equation at the same time they try to increase the supply side.

The supplements in this guide address exactly those three pressure points: build more, lose less, recycle better.

The Supplements That Matter Most on NAD+

There are no dose numbers on this page. The right amount of each of these depends on your actual protocol, your bloodwork, and what else you are taking, because a number written for the average person will be wrong for most specific ones. That is what the MyPeptidePal app resolves.

What NAD+ Cannot Build Itself Without

NAD+ is a molecule, not a signal. When you supplement it, the goal is to raise the intracellular pool available to your enzymes. But the body does not simply absorb the supplement and park it as free NAD+. It processes it through a biosynthetic pathway that has its own requirements, its own bottlenecks, and its own downstream consequences. The cofactors here are not nice-to-haves. For a meaningful share of people, they are what determine whether the pool actually rises.

TMG

TMG, trimethylglycine, is the most important co-supplement in a NAD+ protocol, and understanding why requires a brief look at what happens when NAD+ metabolism speeds up.

NAD+ fuels three major enzyme families: sirtuins (the gene-regulation proteins), PARPs (the DNA repair enzymes), and NNMT (an enzyme that clears a NAD+ breakdown product called nicotinamide). All three consume methyl groups as part of their activity. SIRT1 in particular, the longevity-associated sirtuin that NAD+ supplementation is largely aimed at fueling, drives downstream demand on a methyl-recycling process that relies on a molecule called SAM (S-adenosylmethionine, the body's main methyl donor). When NAD+ activity increases, methyl demand rises across all these pathways simultaneously. If dietary methyl donors are not keeping pace, homocysteine, an intermediate in the methylation cycle, accumulates.

Think of it this way: NAD+ runs the factory faster, but the factory's exhaust requires a cleanup crew. Methyl donors are the cleanup crew. When they run short, the waste product, homocysteine, piles up.

TMG donates methyl groups directly via the betaine-homocysteine pathway (the route that converts homocysteine back to methionine without requiring the B12-dependent step). This is why TMG is the standard co-supplementation recommendation in NAD+ protocols: it provides methyl capacity through a route that does not compete with other demands.

This earns TMG the double-duty designation. It is not just a precautionary side-effect guard. It is addressing a real biochemical consequence of what NAD+ is doing in the body. The clinical basis for homocysteine-lowering by TMG is strong and well-replicated across human trials. The specific connection to NAD+-driven methylation demand is mechanistic rather than directly trial-tested in an NAD+ supplementation population, which is the honest distinction to draw. The mechanism is coherent, the safety profile of TMG is excellent, and the cost of getting it wrong points in one direction: homocysteine rises, DNA damage increases, and NAD+ is consumed faster by the repair activity that responds to that damage.

Magnesium

Magnesium is a required cofactor for two specific enzymes in NAD+ biosynthesis. The first is the enzyme that adds the adenine portion to complete the NAD+ molecule (nicotinamide mononucleotide adenylyltransferase, for reference, but what matters is its function: it is the final assembly step). The second is the enzyme that phosphorylates nicotinamide riboside so it can enter the synthesis pathway at all. Without adequate magnesium inside the cell, both of these steps slow down regardless of how much precursor is circulating.

The clinical evidence for magnesium's cofactor role in these enzymes is well-established in the biochemistry literature. What is less commonly appreciated is that roughly half of all magnesium deficiency is missed by standard serum panels, because serum magnesium is tightly regulated and only falls when stores are severely depleted. RBC magnesium, which measures the intracellular concentration directly, is the right marker here. A person whose serum magnesium looks normal but whose RBC magnesium is low may have a meaningful synthesis bottleneck that standard bloodwork would not catch.

Magnesium glycinate is generally well tolerated when GI sensitivity is a concern, which it often is alongside a NAD+ protocol that may already cause some GI adjustment during the first week.

Folate (L-methylfolate)

Folate works alongside TMG to close the methylation loop. Where TMG donates methyl groups through the betaine-homocysteine pathway, folate in its active methylated form donates methyl groups through the methionine synthase pathway, which uses B12 as a cofactor. Both routes convert homocysteine back to methionine, and both are necessary because the two pathways are not interchangeable: tissue distribution, enzyme saturation, and individual genetic variation mean that relying on one alone leaves gaps.

When NAD+ metabolism accelerates methylation demand, folate and TMG together provide coverage through two independent routes. The clinical evidence for folate's role in homocysteine management is among the strongest in nutritional medicine. The connection to NAD+ activity is mechanistic, but the pathway is direct and folate insufficiency in the general population is common enough to make this a practical consideration rather than a theoretical one.

One practical note: L-methylfolate is the active form that bypasses the conversion enzyme many people have genetic variants in. Standard folic acid requires a conversion step that individuals with common variants in the MTHFR enzyme (the protein that converts dietary folate into the usable form) carry out poorly. L-methylfolate works whether or not that conversion step is functioning normally.

Vitamin D3

Vitamin D's role here is one step upstream of magnesium. Vitamin D regulates intestinal absorption of magnesium: it signals the gut to take up more magnesium from food. Deficiency does not mean zero magnesium is absorbed, but it does mean the absorption signal is weaker. In someone whose dietary magnesium intake is only adequate rather than generous, that reduced signal can translate into the intracellular deficit that slows NAD+ synthesis.

The chain runs: low vitamin D leads to reduced magnesium absorption, which leads to lower RBC magnesium, which limits how fast the biosynthetic enzymes can assemble NAD+ from precursors. This is an indirect path rather than a direct one, and the evidence connecting vitamin D specifically to NAD+ synthesis efficiency is mechanistic rather than supported by a dedicated human trial. But vitamin D deficiency is widespread in modern populations, its effects on magnesium absorption are well-established, and the downstream consequence for NAD+ biosynthesis is a coherent extension of mechanisms that are individually solid.

Vitamin D3 is the form that raises circulating vitamin D status most reliably. It is typically taken alongside vitamin K2, which directs calcium appropriately, since vitamin D supplementation increases calcium absorption and K2 determines where that calcium is deposited.

What Amplifies the Result NAD+ Is Already Producing

Once the NAD+ pool is adequately supplied and the methylation machinery is supported, the next question is what activates the downstream enzymes the pool is meant to fuel, and what prevents that pool from being degraded before it reaches them. That is what the synergists address.

Resveratrol

Resveratrol is a plant polyphenol that activates SIRT1, the longevity-associated sirtuin that NAD+ supplementation is largely aimed at fueling. The mechanism runs through two routes: resveratrol directly changes the enzyme's shape in a way that makes it more active at the same NAD+ concentration, and it activates a cellular energy sensor called AMPK that independently drives sirtuin activity and the process of building new mitochondria.

The relationship to NAD+ is synergistic in the strict sense: resveratrol increases the enzyme's sensitivity and activity level while NAD+ ensures the cosubstrate those enzymes require is actually available. More active enzymes running against a depleted substrate pool produce modest gains at best. An adequate substrate pool with low enzyme activity is equally limited. The combination addresses both inputs to the same node.

The human clinical data on resveratrol is mixed. In vitro and animal studies show robust effects; human trials show more modest and variable results. Its use alongside NAD+ in longevity protocols is widespread, grounded in a coherent mechanism, and currently ahead of the human trial data that would confirm the synergy directly. Resveratrol is best absorbed when taken with a meal containing dietary fat.

One practical note: resveratrol may magnify both the effects and the side effects of NAD+ supplementation. Starting with a lower dose and building gradually is the sensible approach. This is covered in the cautions section below.

Apigenin or Quercetin

Apigenin and quercetin are both CD38 inhibitors, meaning they slow the enzyme that breaks NAD+ down most aggressively. Understanding why that matters requires understanding what CD38 actually does.

CD38 is an enzyme expressed widely in immune cells and other tissues. Its job is to cleave NAD+ into smaller molecules, primarily a calcium-signaling messenger the body uses in immune activity and cardiac function. In young, healthy tissue, CD38 activity is modest. With age and with chronic inflammation, CD38 expression rises substantially, and it becomes one of the most aggressive drains on the NAD+ pool. Animal model research suggests that rising CD38 activity accounts for a meaningful portion of the NAD+ decline associated with aging, though direct human evidence for the magnitude of this effect is still accumulating.

Apigenin and quercetin, both flavonoids found widely in plants, inhibit CD38. By slowing its activity, they reduce the rate at which the NAD+ pool is degraded between doses. This is a different approach from the precursor and cofactor strategies: instead of adding more substrate, they slow the drain.

This earns apigenin and quercetin the double-duty designation. They serve as synergists by protecting the pool in real time, and as result-preservation supplements by maintaining the elevation that supplementation has built over time. The animal model evidence for CD38 inhibition by these compounds is reasonably strong. Direct human trial data for their use in NAD+ protocols is limited as of 2026; what exists is a well-supported mechanism and consistent user-reported experience from longevity protocols. The two compounds are not identical and can be used separately or together. Quercetin has a broader evidence base across other health applications; apigenin is more specific to the CD38 inhibition pathway in the longevity context.

CoQ10

CoQ10 sits at the downstream end of the NAD+ pathway, and its role is easy to miss if you think of NAD+ only as a longevity molecule rather than a metabolic one.

Here is what actually happens inside a mitochondrion: NAD+ accepts electrons during the cell's core energy-processing steps, becoming NADH (the reduced, electron-loaded form). NADH then delivers those electrons to the mitochondrial electron transport chain, a series of protein complexes that use the electrons to pump protons and ultimately produce ATP. CoQ10 is the small mobile carrier that shuttles electrons between the first two complexes and the third, where the bulk of ATP generation happens.

When CoQ10 is low, electrons back up at the early complexes. NADH cannot offload its electrons, the ratio shifts toward the reduced electron-loaded form, and the amount of free NAD+ available to sirtuins and PARP decreases. The supplementation is still raising the total pool, but the effective free NAD+ that determines enzyme activity is being compressed from the downstream side.

CoQ10 declines with age and is further reduced by statin medications, which is relevant because NAD+ supplementation is common among people also taking statins. Ubiquinol is the reduced, active form that is better absorbed than the oxidized form, particularly in older adults.

The evidence base for CoQ10 in mitochondrial function is well-established for populations with deficiency or statin use. Its specific role in maximizing NAD+ efficiency is mechanistically coherent but less directly studied as a combination. The mechanism is real; the magnitude of benefit in someone who is already replete in CoQ10 is less certain.

Protecting the Results NAD+ Works to Build

Creatine

Creatine's place in this stack is about the muscle side of the equation. NAD+ supplementation supports mitochondrial efficiency and sirtuin-mediated metabolic regulation over months of sustained use. What it does not directly address is the phosphocreatine buffer that powers short, high-intensity contractions, or the lean mass retention that determines whether NAD+-supported metabolic health translates into actual physical capacity as you age.

Creatine monohydrate has very strong randomized-trial evidence for increasing muscle mass, strength, and power output, particularly in older adults where the relationship between mitochondrial decline and muscle loss is most clinically relevant to a NAD+ protocol. Some research suggests that older adults taking both creatine and an NAD+ precursor together may see improvements in cognitive measures beyond what either produces alone, though this signal awaits replication in a larger, dedicated trial before conclusions can be drawn.

The mechanism complement is real regardless of whether the combination has been formally trialed: creatine handles the fast energy system (phosphocreatine buffer, zero to roughly thirty seconds of peak effort), while NAD+ supports the slow energy system (mitochondrial energy production, sustained output over minutes and hours). Supporting both simultaneously is more complete than supporting either alone.

One note for bloodwork monitoring: creatine supplementation raises serum creatinine as a routine metabolic byproduct. Elevated creatinine in someone taking creatine without other signs of kidney stress is expected and benign. It is worth flagging on a bloodwork review so it is not misread as evidence of renal impairment.

Cautions and Interactions

If You Are on Warfarin, Immunosuppressants, PARP Inhibitors, or Chemotherapy

These are not cautionary notes to keep in mind. They are reasons to involve a prescriber before you start NAD+ supplementation.

NAD+ has no established interaction with warfarin, and that is worth stating plainly because the opposite is widely repeated. Supplement pages commonly describe NAD+ speeding up warfarin clearance through CYP2C9, the liver enzyme that breaks warfarin down, and conclude that INR drops and clotting risk rises. There is no human evidence for it. Nicotinamide riboside is cleared by kinase and salvage pathways rather than by the CYP450 enzymes that handle warfarin, and no published case report describes NAD+ or nicotinamide riboside changing anyone's INR.

One genuine caution belongs to the wider vitamin B3 family, and it points the other way. A published case report describes a woman whose warfarin had been stable for eighteen months and whose INR rose from 2.4 to above 12.3 after her extended-release nicotinic acid dose was doubled. Nicotinic acid is a different form of vitamin B3 from the precursors used in NAD+ products, the proposed mechanism was reduced clotting factor availability rather than any liver enzyme effect, and the direction of harm was bleeding rather than clotting. That report should not be carried over to NAD+, and it is emphatically not a reason to raise a warfarin dose.

The practical position is simpler than either story. Anticoagulation has a narrow margin and individual response varies, so a prescriber should know about any supplement being added, including this one. That is general good practice, not a documented NAD+ interaction.

NAD+ precursors are sometimes described as raising the activity of CYP3A4 and P-glycoprotein, the enzyme and transporter that govern blood levels of most immunosuppressant drugs including tacrolimus, cyclosporine, and sirolimus. That mechanism is unconfirmed: no human study has measured it, and the long-term nicotinamide riboside safety trials report no findings on either pathway. The caution still stands, on different grounds. Trough levels in a transplant recipient have very little room for error and the consequence of getting them wrong is graft rejection, so this combination warrants direct specialist involvement regardless of whether the proposed mechanism turns out to be real.

NAD+ supplementation replenishes the substrate that PARP inhibitor cancer drugs are specifically designed to deplete. Olaparib, rucaparib, and niraparib work by starving PARP enzymes of their cosubstrate, which prevents cancer cells from repairing the DNA damage that treatment is intended to cause. Adding NAD+ directly antagonizes that mechanism. At the same time, increased CYP3A4 activity from NAD+ precursors lowers plasma levels of many chemotherapy agents, potentially reducing treatment efficacy through a separate pathway.

Active cancer patients should not combine NAD+ with oncology treatment without oncologist guidance.

Other Interactions Worth Monitoring

Diabetes medications including insulin, metformin, and sulfonylureas deserve attention because NAD+ improves insulin sensitivity and glucose handling. This is a benefit when taken alone, but combined with drugs that are already lowering blood glucose, the additive effect can produce hypoglycemia. Anyone managing blood sugar with medication should monitor glucose carefully and involve their prescriber when adding NAD+ to their protocol.

Antihypertensive medications carry a parallel concern: NAD+ has modest blood pressure effects, and combining it with lisinopril, metoprolol, or losartan may push blood pressure lower than intended.

High-dose niacin, specifically nicotinic acid at or above roughly one gram per day, should not be combined with NAD+ or NMN/NR. They share the same biosynthetic salvage pathway, and stacking them creates redundant pathway burden and additional GI stress without proportional benefit. This is a supplement interaction rather than a medication interaction, but the mechanism is real.

Resveratrol may magnify both the effects and the side effects of NAD+ supplementation, as noted in its section above. Starting with a lower dose of each and titrating upward is sensible. Do not stack multiple NAD+ precursors simultaneously. NR, NMN, and direct NAD+ all feed the same pathway; combining two or three creates redundant stress without proportional additional benefit.

Frequently Asked Questions

How much of each supplement should I take with NAD+?

There are no dose numbers on this page, and that is intentional. The right amount of TMG, magnesium, resveratrol, or any other supplement in this stack depends on your actual NAD+ protocol, your baseline bloodwork (particularly homocysteine, RBC magnesium, and vitamin D status), and what medications or other supplements you are already taking. A dose written for the average person misses the wide range of individual situations that actually determine the answer. The MyPeptidePal app works this out from your specific inputs.

Which blood markers actually matter when running NAD+?

Homocysteine is the most important one to watch, because NAD+ metabolism increases methylation demand and homocysteine rises when that demand is not met. RBC magnesium (not serum magnesium, which is insensitive to early deficiency) reflects whether the cofactor needed for NAD+ synthesis is adequate. If you have access to whole-blood NAD+ testing, it is the most direct confirmation that supplementation is actually raising your cellular pool. HbA1c and fasting glucose matter if metabolic improvement is part of your goal. Anyone on warfarin needs INR monitored before and during the protocol given the CYP2C9 interaction described in the cautions section.

Does NAD+ interact with prescription medications I might be taking?

It can, and the risks are not uniformly minor. The interactions with warfarin, immunosuppressants, PARP inhibitors, and chemotherapy are serious enough that they should be resolved with a prescriber before you start, not after. For blood pressure and blood sugar medications, the concern is additive lowering rather than a direct pharmacokinetic clash, which still deserves clinical awareness. The cautions section of this guide covers each interaction in detail.

Do I need to keep taking these supplements after I stop NAD+?

TMG and folate support the methylation cycle regardless of NAD+ supplementation, so many people continue them as ongoing nutritional support. Magnesium and vitamin D are similarly useful independent of any specific protocol. The CD38 inhibitors and resveratrol are most directly valuable in the context of sirtuin and NAD+ pathway activity, so their rationale is more closely tied to NAD+ use. Creatine has strong standalone evidence for muscle and cognitive benefits that do not depend on NAD+ at all. Whether to continue each one after stopping NAD+ depends on what each was doing for you individually and what your bloodwork shows.

Can I just take a good multivitamin instead of this stack?

A multivitamin will not replace this stack. The TMG needed to keep up with NAD+-driven methylation demand is well above what any multivitamin provides. Most multivitamins use folic acid rather than L-methylfolate, which matters for anyone who cannot convert it efficiently due to genetic variants in the relevant conversion enzyme. The CD38 inhibitors and CoQ10 that address the NAD+ degradation and downstream electron transport issues are not found in standard multivitamins at useful amounts. A high-quality multivitamin can serve as a nutritional foundation, but the specific functional gaps this stack addresses require targeted supplementation.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of NAD+ and the nutrients that support it in one place.